These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 24167028)
1. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Hanna-Mitchell AT; Wolf-Johnston AS; Barrick SR; Kanai AJ; Chancellor MB; de Groat WC; Birder LA Neurourol Urodyn; 2015 Jan; 34(1):79-84. PubMed ID: 24167028 [TBL] [Abstract][Full Text] [Related]
2. Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. Liu HT; Chen SH; Chancellor MB; Kuo HC PLoS One; 2015; 10(8):e0134803. PubMed ID: 26241848 [TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Smith CP; Gangitano DA; Munoz A; Salas NA; Boone TB; Aoki KR; Francis J; Somogyi GT Neurochem Int; 2008 May; 52(6):1068-75. PubMed ID: 18187233 [TBL] [Abstract][Full Text] [Related]
4. Targets for botulinum toxin in the lower urinary tract. Cruz F Neurourol Urodyn; 2014 Jan; 33(1):31-8. PubMed ID: 23775898 [TBL] [Abstract][Full Text] [Related]
5. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Smith CP; Vemulakonda VM; Kiss S; Boone TB; Somogyi GT Neurochem Int; 2005 Sep; 47(4):291-7. PubMed ID: 15970360 [TBL] [Abstract][Full Text] [Related]
6. Re: Hanna-Mitchell AT, Wolf-Johnston AS, Barrick SR, et al. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol Urodyn 2015;34:79-84. Lavelle JP Neurourol Urodyn; 2015 Jan; 34(1):85. PubMed ID: 24151021 [No Abstract] [Full Text] [Related]
7. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Khera M; Somogyi GT; Kiss S; Boone TB; Smith CP Neurochem Int; 2004 Dec; 45(7):987-93. PubMed ID: 15337297 [TBL] [Abstract][Full Text] [Related]
8. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Kuo HC; Liu HT; Chuang YC; Birder LA; Chancellor MB Eur Urol; 2014 Jun; 65(6):1117-24. PubMed ID: 24555904 [TBL] [Abstract][Full Text] [Related]
9. BoNT/A in the Urinary Bladder-More to the Story than Silencing of Cholinergic Nerves. Ibrahim H; Maignel J; Hornby F; Daly D; Beard M Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051030 [TBL] [Abstract][Full Text] [Related]
10. Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. Chuang YC; Huang TL; Tyagi P; Huang CC J Urol; 2016 Aug; 196(2):599-608. PubMed ID: 26724396 [TBL] [Abstract][Full Text] [Related]
11. Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder. Beckel JM; Daugherty SL; Tyagi P; Wolf-Johnston AS; Birder LA; Mitchell CH; de Groat WC J Physiol; 2015 Apr; 593(8):1857-71. PubMed ID: 25630792 [TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder. Chen SF; Chang CH; Kuo HC Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005 [TBL] [Abstract][Full Text] [Related]
13. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity. Ha US; Park EY; Kim JC Urology; 2011 Sep; 78(3):721.e1-721.e6. PubMed ID: 21782224 [TBL] [Abstract][Full Text] [Related]
14. Bradykinin modulates spontaneous nerve growth factor production and stretch-induced ATP release in human urothelium. Ochodnický P; Michel MB; Butter JJ; Seth J; Panicker JN; Michel MC Pharmacol Res; 2013 Apr; 70(1):147-54. PubMed ID: 23376352 [TBL] [Abstract][Full Text] [Related]
15. Mucosal modulation of contractility in bladder strips from normal and overactive rat models and the effect of botulinum toxin A on overactive bladder strips. Campbell PC; McDonnell B; Monaghan KP; Baysting L; Little O; McCloskey KD Neurourol Urodyn; 2017 Apr; 36(4):1052-1060. PubMed ID: 27494539 [TBL] [Abstract][Full Text] [Related]
16. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. Lawrence GW; Aoki KR; Dolly JO J Pharmacol Exp Ther; 2010 Sep; 334(3):1080-6. PubMed ID: 20576797 [TBL] [Abstract][Full Text] [Related]
17. Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A. Dolly JO; Lawrence GW Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S14-20. PubMed ID: 25042137 [TBL] [Abstract][Full Text] [Related]
18. Effect of short-term androgen deficiency on bladder contractility and urothelial mediator release. Bravo G; Massa H; Rose'Meyer R; Chess-Williams R; McDermott C; Sellers DJ Naunyn Schmiedebergs Arch Pharmacol; 2017 May; 390(5):547-556. PubMed ID: 28190243 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Lin YH; Chiang BJ; Liao CH Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522 [TBL] [Abstract][Full Text] [Related]
20. Purinergic and muscarinic modulation of ATP release from the urothelium and its paracrine actions. Sui G; Fry CH; Montgomery B; Roberts M; Wu R; Wu C Am J Physiol Renal Physiol; 2014 Feb; 306(3):F286-98. PubMed ID: 24285497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]